CABG still preferred over PCI in patients with triple vessel disease

August 29, 2011 in Cardiology

Results from CREDO-Kyoto PCI/CABG Registry Cohort-2 show that percutaneous coronary intervention (PCI) was associated with significantly higher risk for serious adverse events in patients with triple vessel disease than coronary artery bypass grafting (CABG). The protective effect of CABG for myocardial infarction was described as "especially remarkable". In view of these results, said investigator Dr Hiroki Shiomi from Kyoto University Hospital in Japan, "CABG would still remain the standard treatment option in patients with triple vessel disease, particularly when their SYNTAX scores are high".

These registry findings, derived from the largest ever study population of triple patients with SYNTAX score assessment, are consistent with those found in the SYNTAX randomised trial. However, said Dr Shiomi, while the observations were striking in patients with triple vessel disease, the selection of revascularisation strategies in patients with less complex coronary anatomy "deserves further consideration".

As background to the report, he explained that PCI has been widely performed in patients with severe (such as left main or triple vessel ) following the introduction of drug-eluting stents. However, long-term of PCI relative to CABG in such patients have not yet been adequately evaluated. Although three-year results from the SYNTAX trial suggested that an excess risk of PCI relative to CABG for death, myocardial infarction or stroke was significant in the triple vessel disease subset, there were limitations in the apparent lack of statistical power to evaluate this composite endpoint.

The CREDO-Kyoto (Coronary REvascularization Demonstrating Outcome Study in Kyoto) PCI/CABG registry cohort-2 is a physician-initiated non-company sponsored 26-centre registry enrolling consecutive patients having a first coronary revascularisation between January 2005 and December 2007. The study population for the current analysis consisted of 2981 patients with triple vessel disease (PCI 1825 patients, and CABG 1156 patients). To ensure comparability between the PCI and CABG groups (in an observational study), anatomic complexities of coronary artery disease were assessed by using the SYNTAX score.

The primary endpoint of the study was a composite of all-cause death, (MI) and stroke. PCI as compared with CABG was associated with a higher 3-year risk for this primary endpoint (adjusted hazard ratio (HR) 1.47 [95% CI 1.13-1.92, P=0.004]) and for MI (HR 2.39 [95% CI 1.31-4.36, P=0.004]). However, the risk for cardiac death was not significantly different (HR 1.30 [95% CI 0.81-2.07, P=0.28]), although the risk for all-cause death was significantly higher after PCI (HR 1.62 [95% CI 1.16-2.27, P=0.005]).

Results also showed that the cumulative incidence of the primary endpoint was comparable between the PCI and CABG groups in patients with low (<23) and intermediate (23-32) SYNTAX scores, but in patients with high SYNTAX scores (≥33) was markedly higher after PCI than after CABG (15.8% and 12.5%, P=0.25, 18.8% and 16.7%, P=0.24, and 27.0% and 16.4%, P=0.004, respectively).

However, the adjusted risk of PCI relative to CABG for the primary endpoint was HR 1.66 (95% CI 1.04-2.65, P=0.03) in the low-score category, HR 1.24 (95% CI 0.83-1.85, P=0.29) in the intermediate-score category, and HR 1.59 (95% CI 0.998-2.54, P=0.051) in the high-score category. "Further studies are therefore warranted to investigate whether is a viable option in patients with less complex coronary anatomy," said Dr Shiomi.

Provided by European Society of Cardiology search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Biodegradable stent proves non-inferior to drug-eluting stent

The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...

Cardiology created 10 hours ago | popularity 5 / 5 (1) | comments 0

Post-approval TAVI registry shows high rates of device success at one year

One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries to-date – reported today at EuroPCR 2013 show good clinical outcomes in routine clinical practice, ...

Cardiology created 10 hours ago | popularity not rated yet | comments 0

Antidepressant reduces stress-induced heart condition

A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.

Cardiology created 11 hours ago | popularity 5 / 5 (1) | comments 0 | with audio podcast

Study identifies superior hypertension treatment, efficacy between sexes

(Medical Xpress)—In a recent subgroup analysis of the largest blood pressure treatment trial in history, University of Alabama at Birmingham (UAB) researchers found that women and men react the same to ...

Cardiology created 19 hours ago | popularity 5 / 5 (1) | comments 0

Evaluating a new way to open clogged arteries

Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments ...

Cardiology created 20 hours ago | popularity 4.7 / 5 (6) | comments 0 | with audio podcast


If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Insight into the dazzling impact of insulin in cells

Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

Drugs found to both prevent and treat Alzheimer's disease in mice

Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.